- Home
- TBRG vs FENC Comparison
TBRG vs FENC Comparison
Compare TBRG & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBRG
- FENC
- Stock Information
- Founded
- TBRG 1979
- FENC 1996
- Country
- TBRG United States
- FENC United States
- Employees
- TBRG N/A
- FENC N/A
- Industry
- TBRG
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TBRG
- FENC Health Care
- Exchange
- TBRG NYSE
- FENC Nasdaq
- Market Cap
- TBRG 186.6M
- FENC 181.7M
- IPO Year
- TBRG N/A
- FENC 2001
- Fundamental
- Price
- TBRG $12.35
- FENC $5.19
- Analyst Decision
- TBRG Buy
- FENC Strong Buy
- Analyst Count
- TBRG 2
- FENC 2
- Target Price
- TBRG $13.50
- FENC $14.00
- AVG Volume (30 Days)
- TBRG 55.4K
- FENC 83.5K
- Earning Date
- TBRG 11-06-2024
- FENC 11-04-2024
- Dividend Yield
- TBRG N/A
- FENC N/A
- EPS Growth
- TBRG N/A
- FENC N/A
- EPS
- TBRG N/A
- FENC 0.10
- Revenue
- TBRG $336,557,000.00
- FENC $48,889,000.00
- Revenue This Year
- TBRG $0.94
- FENC $162.23
- Revenue Next Year
- TBRG $4.58
- FENC $6.86
- P/E Ratio
- TBRG N/A
- FENC $57.28
- Revenue Growth
- TBRG N/A
- FENC 647.88
- 52 Week Low
- TBRG $7.55
- FENC $5.00
- 52 Week High
- TBRG $17.28
- FENC $11.92
- Technical
- Relative Strength Index (RSI)
- TBRG 55.73
- FENC 41.53
- Support Level
- TBRG $11.68
- FENC $5.13
- Resistance Level
- TBRG $12.45
- FENC $5.53
- Average True Range (ATR)
- TBRG 0.40
- FENC 0.25
- MACD
- TBRG -0.07
- FENC 0.01
- Stochastic Oscillator
- TBRG 59.48
- FENC 30.49
About TBRG TRUBRIDGE INC
TruBridge Inc is a provider of healthcare solutions and services for community hospitals, clinics, and other healthcare systems. It provides services such as Electronic health records & information systems, revenue cycle management, population health, and data management, etc. The segments of the company are RCM, EHR, and Patient Engagement. The company derives maximum revenue from the RCM segment.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.